vs
Intellia Therapeutics, Inc.（NTLA）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是Intellia Therapeutics, Inc.的1.2倍（$27.1M vs $23.0M），Rumble Inc.净利率更高（-120.8% vs -416.2%，领先295.4%），Intellia Therapeutics, Inc.同比增速更快（78.8% vs -10.5%），Rumble Inc.自由现金流更多（$-31.7M vs $-69.4M），过去两年Rumble Inc.的营收复合增速更高（15.2% vs -10.8%）
Intellia Therapeutics是美国临床阶段生物技术企业，专注于依托CRISPR技术开发具有潜在治愈效果的创新疗法。公司体内项目采用静脉注射CRISPR疗法，通过专属递送技术可在特定靶组织内精准编辑致病基因；体外项目则利用CRISPR改造细胞制备治疗产品，主攻未被满足的医疗需求。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
NTLA vs RUM — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $23.0M | $27.1M |
| 净利润 | $-95.8M | $-32.7M |
| 毛利率 | — | 5.5% |
| 营业利润率 | -428.9% | -131.1% |
| 净利率 | -416.2% | -120.8% |
| 营收同比 | 78.8% | -10.5% |
| 净利润同比 | 25.7% | 86.2% |
| 每股收益（稀释后） | $-0.81 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $23.0M | $27.1M | ||
| Q3 25 | $13.8M | $24.8M | ||
| Q2 25 | $14.2M | — | ||
| Q1 25 | $16.6M | $23.7M | ||
| Q4 24 | $12.9M | $30.2M | ||
| Q3 24 | $9.1M | $25.1M | ||
| Q2 24 | $7.0M | $22.5M | ||
| Q1 24 | $28.9M | $17.7M |
| Q4 25 | $-95.8M | $-32.7M | ||
| Q3 25 | $-101.3M | $-16.3M | ||
| Q2 25 | $-101.3M | — | ||
| Q1 25 | $-114.3M | $-2.7M | ||
| Q4 24 | $-128.9M | $-236.8M | ||
| Q3 24 | $-135.7M | $-31.5M | ||
| Q2 24 | $-147.0M | $-26.8M | ||
| Q1 24 | $-107.4M | $-43.3M |
| Q4 25 | — | 5.5% | ||
| Q3 25 | — | -1.8% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -26.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | — | -45.4% | ||
| Q2 24 | — | -58.8% | ||
| Q1 24 | — | -79.5% |
| Q4 25 | -428.9% | -131.1% | ||
| Q3 25 | -808.9% | -113.6% | ||
| Q2 25 | -772.2% | — | ||
| Q1 25 | -726.6% | -153.5% | ||
| Q4 24 | -1059.9% | -80.1% | ||
| Q3 24 | -1589.0% | -131.0% | ||
| Q2 24 | -1998.6% | -172.7% | ||
| Q1 24 | -394.0% | -197.4% |
| Q4 25 | -416.2% | -120.8% | ||
| Q3 25 | -735.2% | -65.7% | ||
| Q2 25 | -710.8% | — | ||
| Q1 25 | -687.6% | -11.2% | ||
| Q4 24 | -1001.2% | -783.2% | ||
| Q3 24 | -1489.5% | -125.9% | ||
| Q2 24 | -2112.6% | -119.2% | ||
| Q1 24 | -371.3% | -244.1% |
| Q4 25 | $-0.81 | $-0.13 | ||
| Q3 25 | $-0.92 | $-0.06 | ||
| Q2 25 | $-0.98 | — | ||
| Q1 25 | $-1.10 | $-0.01 | ||
| Q4 24 | $-1.27 | $-1.17 | ||
| Q3 24 | $-1.34 | $-0.15 | ||
| Q2 24 | $-1.52 | $-0.13 | ||
| Q1 24 | $-1.12 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $449.9M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $671.4M | $274.8M |
| 总资产 | $842.1M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $449.9M | $237.9M | ||
| Q3 25 | $511.0M | $269.8M | ||
| Q2 25 | $459.7M | — | ||
| Q1 25 | $503.7M | $301.3M | ||
| Q4 24 | $601.5M | $114.0M | ||
| Q3 24 | $658.1M | $132.0M | ||
| Q2 24 | $691.1M | $154.2M | ||
| Q1 24 | $791.3M | $183.8M |
| Q4 25 | $671.4M | $274.8M | ||
| Q3 25 | $748.4M | $302.2M | ||
| Q2 25 | $715.3M | — | ||
| Q1 25 | $779.9M | $339.6M | ||
| Q4 24 | $872.0M | $-63.1M | ||
| Q3 24 | $962.6M | $166.1M | ||
| Q2 24 | $971.1M | $192.7M | ||
| Q1 24 | $1.0B | $210.7M |
| Q4 25 | $842.1M | $336.8M | ||
| Q3 25 | $925.3M | $367.2M | ||
| Q2 25 | $898.9M | — | ||
| Q1 25 | $986.2M | $391.1M | ||
| Q4 24 | $1.2B | $195.3M | ||
| Q3 24 | $1.2B | $217.2M | ||
| Q2 24 | $1.2B | $243.2M | ||
| Q1 24 | $1.3B | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-69.3M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-69.4M | $-31.7M |
| 自由现金流率自由现金流/营收 | -301.6% | -117.2% |
| 资本支出强度资本支出/营收 | 0.5% | 8.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-395.9M | $-70.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-69.3M | $-29.4M | ||
| Q3 25 | $-76.9M | $-10.6M | ||
| Q2 25 | $-99.6M | — | ||
| Q1 25 | $-148.9M | $-14.5M | ||
| Q4 24 | $-85.2M | $-12.4M | ||
| Q3 24 | $-84.8M | $-19.1M | ||
| Q2 24 | $-58.2M | $-21.7M | ||
| Q1 24 | $-120.7M | $-33.9M |
| Q4 25 | $-69.4M | $-31.7M | ||
| Q3 25 | $-76.9M | $-12.0M | ||
| Q2 25 | $-99.9M | — | ||
| Q1 25 | $-149.7M | $-14.6M | ||
| Q4 24 | $-86.2M | $-12.4M | ||
| Q3 24 | $-86.1M | $-19.9M | ||
| Q2 24 | $-59.2M | $-23.1M | ||
| Q1 24 | $-123.2M | $-34.3M |
| Q4 25 | -301.6% | -117.2% | ||
| Q3 25 | -558.2% | -48.6% | ||
| Q2 25 | -701.0% | — | ||
| Q1 25 | -900.1% | -61.7% | ||
| Q4 24 | -669.4% | -40.9% | ||
| Q3 24 | -945.2% | -79.5% | ||
| Q2 24 | -850.9% | -102.8% | ||
| Q1 24 | -425.7% | -193.3% |
| Q4 25 | 0.5% | 8.5% | ||
| Q3 25 | 0.2% | 5.7% | ||
| Q2 25 | 1.7% | — | ||
| Q1 25 | 4.4% | 0.6% | ||
| Q4 24 | 7.6% | 0.1% | ||
| Q3 24 | 14.0% | 3.4% | ||
| Q2 24 | 14.5% | 6.1% | ||
| Q1 24 | 8.7% | 2.4% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
